Developer docs
API playgroundTry for free, no card

Search company profiles

Phanes Therapeutics

Full company profile

uuid0000m9w

Namestring
Phanes Therapeutics
Legal namestring
Phanes Therapeutics, Inc.
Websiteurl
phanesthera.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Phanes Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California, focused on discovering and developing therapeutics for solid tumors and eye diseases. The company's lead product candidate is spevatamig (PT886), a first-in-class bispecific antibody that simultaneously targets CLDN18.2 and CD47, functioning as an innate immunity enhancer designed to address immunologically cold tumors resistant to conventional immunotherapies. Spevatamig has received both FDA Orphan Drug Designation and FDA Fast Track Designation for pancreatic cancer, and is being evaluated in the TWINPEAK basket trial across multiple gastrointestinal malignancies including metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with 160+ patients dosed globally.

The company's core technology centers on bispecific antibody engineering with a novel dual-targeting architecture. Phase 2 clinical data presented at ASCO 2026 demonstrated a 52.4% objective response rate and 90.5% disease control rate in US patients with metastatic PDAC, with median progression-free survival of 7.3 months and median overall survival of 14.7 months, alongside a favorable safety profile with no cytokine release syndrome or dose-limiting toxicities observed. These results support advancement toward a Phase 3 registrational trial.

Phanes operates a pre-commercial business model with no current product revenue. Revenue will be generated through future pharmaceutical product sales upon regulatory approval. The company has established a strategic collaboration with Merck to evaluate spevatamig in combination with pembrolizumab (Keytruda), signaling an enterprise partnership approach for potential co-commercialization in oncology. Funding to date includes a $40 million Series B led by HSG in 2021 and subsequent investment from Kaitai Capital in 2024.

Short descriptiontext

Phanes Therapeutics is a clinical-stage biotech developing spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47 for metastatic pancreatic cancer, biliary tract cancer, and other solid tumors, with FDA Orphan Drug and Fast Track designations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
bispecific antibody therapeutics, oncology drug development, pancreatic cancer treatment, clinical-stage biotechnology, innate immunity enhancers
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-commercial stage company with drug candidate spevatamig in Phase 2 clinical trials. Revenue will be generated through future pharmaceutical product sales upon regulatory approval.

aijourn.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Phanes Therapeutics is a clinical-stage biotech developing spevatamig (PT886), a first-in-class bispecific antibody that simultaneously targets CLDN18.2 and CD47 to act as an innate immunity enhancer for solid tumors. The lead program focuses on metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with the candidate having received FDA orphan drug and Fast Track designations for pancreatic cancer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 52.4% objective response rate in 2 mg/kg QW cohort in US patients with metastatic PDAC
+4 more records
Product overview1 text field

Phanes Therapeutics is a clinical-stage biotech company focused on oncology drug discovery. The company's lead product is spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47. The drug is being developed as an innate immunity enhancer for the treatment of multiple gastrointestinal cancers, including metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with the goal of addressing cold tumors resistant to conventional immunotherapies. The TWINPEAK basket trial is evaluating spevatamig across multiple cancer types.

Product and service1 record
1Spevatamig (PT886)
CategoryDrug candidate
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Merck (known as MSD outside the US and Canada) to explore spevatamig in combination with pembrolizumab (Keytruda), a PD-1 inhibitor. This strategic partnership aims to evaluate the combination of spevatamig's innate immunity enhancement mechanism with Merck's established checkpoint inhibitor therapy.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of ivonescimab (PD-1/VEGF bispecific) and CLDN18.2-targeting bispecifics. Comparable clinical-stage bispecific antibody pipeline in oncology with combinations in pancreatic and GI cancers.

TypeDirect peer
Description

Approved zolbetuximab (Vyloy), the first CLDN18.2-directed therapy, in gastric/GEJ cancer. Astellas is the leading CLDN18.2 competitor and validates the target class for Phanes' spevatamig.

TypeDirect peer
Description

Chinese biotech with multiple CLDN18.2 bispecific and ADC candidates in oncology, including combinations with checkpoint inhibitors. Directly competes with Phanes in CLDN18.2 GI cancer indications.

TypeDirect peer
Description

Clinical-stage biotech with multiple bispecific antibody programs (e.g., enoblituzumab, MGC018) in oncology. Comparable bispecific platform company competing in solid tumor indications.

TypeDirect peer
Description

Clinical-stage bispecific antibody platform company with candidates in oncology, including zanidatamab (HER2 bispecific). Comparable in modality (bispecific antibodies) and stage (Phase 2/3 oncology).

TypeDirect peer
Description

Clinical-stage computational biology company with a bispecific antibody pipeline (e.g., COM701 PVRIG) in oncology. Comparable mid-stage clinical biotech developing innovative immuno-oncology bispecifics.

TypeDirect peer
Description

Developer of KN046 (PD-L1/CTLA-4 bispecific) and other bispecific antibodies in oncology. Comparable clinical-stage bispecific antibody company targeting solid tumors.

8Dragonfly Therapeutics
TypeDirect peer
Description

Clinical-stage company developing cytokine-based and NK cell engager bispecific antibodies for solid tumors. Comparable bispecific antibody platform in oncology with similar patient-focused development strategy.

TypeDirect peer
Description

Korean biotech developing bispecific antibodies including CLDN18.2 x 4-1BB and other oncology bispecifics. Comparable bispecific antibody pipeline competing in the same target class.

TypeBroad incumbent
Description

Large commercial-stage oncology biotech with tislelizumab and a broad pipeline including bispecific efforts. While much larger, BeiGene represents the end-state for a successful clinical-stage oncology bispecific developer and serves as a comparable benchmark for Phanes' strategic trajectory.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phanes Therapeutics

Oncology Biopharmaceuticalsphanesthera.com

Phanes Therapeutics is a clinical-stage biotech developing spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47 for metastatic pancreatic cancer, biliary tract cancer, and other solid tumors, with FDA Orphan Drug and Fast Track designations.

What Phanes Therapeutics does

Phanes Therapeutics is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in San Diego, California, focused on discovering and developing therapeutics for solid tumors and eye diseases. The company's lead product candidate is spevatamig (PT886), a first-in-class bispecific antibody that simultaneously targets CLDN18.2 and CD47, functioning as an innate immunity enhancer designed to address immunologically cold tumors resistant to conventional immunotherapies. Spevatamig has received both FDA Orphan Drug Designation and FDA Fast Track Designation for pancreatic cancer, and is being evaluated in the TWINPEAK basket trial across multiple gastrointestinal malignancies including metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with 160+ patients dosed globally.

The company's core technology centers on bispecific antibody engineering with a novel dual-targeting architecture. Phase 2 clinical data presented at ASCO 2026 demonstrated a 52.4% objective response rate and 90.5% disease control rate in US patients with metastatic PDAC, with median progression-free survival of 7.3 months and median overall survival of 14.7 months, alongside a favorable safety profile with no cytokine release syndrome or dose-limiting toxicities observed. These results support advancement toward a Phase 3 registrational trial.

Phanes operates a pre-commercial business model with no current product revenue. Revenue will be generated through future pharmaceutical product sales upon regulatory approval. The company has established a strategic collaboration with Merck to evaluate spevatamig in combination with pembrolizumab (Keytruda), signaling an enterprise partnership approach for potential co-commercialization in oncology. Funding to date includes a $40 million Series B led by HSG in 2021 and subsequent investment from Kaitai Capital in 2024.

Phanes Therapeutics firmographics

Firmographics
Name
Phanes Therapeutics
Legal name
Phanes Therapeutics, Inc.
Website
https://phanesthera.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Phanes Therapeutics is a clinical-stage biotech developing spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47 for metastatic pancreatic cancer, biliary tract cancer, and other solid tumors, with FDA Orphan Drug and Fast Track designations.
Ownership category
akta.pro rank

Phanes Therapeutics industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)

Keywords

  • Bispecific antibody therapeutics
  • Oncology drug development
  • Pancreatic cancer treatment
  • Clinical-stage biotechnology
  • Innate immunity enhancers

Where Phanes Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Phanes Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-commercial stage company with drug candidate spevatamig in Phase 2 clinical trials. Revenue will be generated through future pharmaceutical product sales upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Phanes Therapeutics product offering

Product offering

Core offering

Phanes Therapeutics is a clinical-stage biotech developing spevatamig (PT886), a first-in-class bispecific antibody that simultaneously targets CLDN18.2 and CD47 to act as an innate immunity enhancer for solid tumors. The lead program focuses on metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with the candidate having received FDA orphan drug and Fast Track designations for pancreatic cancer.

Product overview

Phanes Therapeutics is a clinical-stage biotech company focused on oncology drug discovery. The company's lead product is spevatamig (PT886), a first-in-class bispecific antibody targeting CLDN18.2 and CD47. The drug is being developed as an innate immunity enhancer for the treatment of multiple gastrointestinal cancers, including metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with the goal of addressing cold tumors resistant to conventional immunotherapies. The TWINPEAK basket trial is evaluating spevatamig across multiple cancer types.

Differentiator

Problem solved

Functional benefit

Products and services

  • Spevatamig (PT886)

Quantifiable outcome

  • 52.4% objective response rate in 2 mg/kg QW cohort in US patients with metastatic PDAC
  • +4 more outcomes

Companies that use Phanes Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Phanes Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Phanes Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MerckcoreStrategic or Co-development PartnerCollaboration with Merck (known as MSD outside the US and Canada) to explore spevatamig in combination with pembrolizumab (Keytruda), a PD-1 inhibitor. This strategic partnership aims to evaluate the combination of spevatamig's innate immunity enhancement mechanism with Merck's established checkpoint inhibitor therapy.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Phanes Therapeutics competitors and assessment

Company assessment

Direct peers

  • Akeso: Developer of ivonescimab (PD-1/VEGF bispecific) and CLDN18.2-targeting bispecifics. Comparable clinical-stage bispecific antibody pipeline in oncology with combinations in pancreatic and GI cancers.
  • Astellas Pharma: Approved zolbetuximab (Vyloy), the first CLDN18.2-directed therapy, in gastric/GEJ cancer. Astellas is the leading CLDN18.2 competitor and validates the target class for Phanes' spevatamig.
  • Innovent Biologics: Chinese biotech with multiple CLDN18.2 bispecific and ADC candidates in oncology, including combinations with checkpoint inhibitors. Directly competes with Phanes in CLDN18.2 GI cancer indications.
  • MacroGenics: Clinical-stage biotech with multiple bispecific antibody programs (e.g., enoblituzumab, MGC018) in oncology. Comparable bispecific platform company competing in solid tumor indications.
  • Zymeworks: Clinical-stage bispecific antibody platform company with candidates in oncology, including zanidatamab (HER2 bispecific). Comparable in modality (bispecific antibodies) and stage (Phase 2/3 oncology).
  • Compugen: Clinical-stage computational biology company with a bispecific antibody pipeline (e.g., COM701 PVRIG) in oncology. Comparable mid-stage clinical biotech developing innovative immuno-oncology bispecifics.
  • Alphamab Oncology: Developer of KN046 (PD-L1/CTLA-4 bispecific) and other bispecific antibodies in oncology. Comparable clinical-stage bispecific antibody company targeting solid tumors.
  • Dragonfly Therapeutics: Clinical-stage company developing cytokine-based and NK cell engager bispecific antibodies for solid tumors. Comparable bispecific antibody platform in oncology with similar patient-focused development strategy.
  • ABL Bio: Korean biotech developing bispecific antibodies including CLDN18.2 x 4-1BB and other oncology bispecifics. Comparable bispecific antibody pipeline competing in the same target class.

Broad incumbents

  • BeiGene: Large commercial-stage oncology biotech with tislelizumab and a broad pipeline including bispecific efforts. While much larger, BeiGene represents the end-state for a successful clinical-stage oncology bispecific developer and serves as a comparable benchmark for Phanes' strategic trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Phanes Therapeutics social profiles

Digital presence

Phanes Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phanes Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Phanes Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phanes Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phanes Therapeutics

What does Phanes Therapeutics do?

Phanes Therapeutics is a clinical-stage biotech developing spevatamig (PT886), a first-in-class bispecific antibody that simultaneously targets CLDN18.2 and CD47 to act as an innate immunity enhancer for solid tumors. The lead program focuses on metastatic pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancer, with the candidate having received FDA orphan drug and Fast Track designations for pancreatic cancer.

Is Phanes Therapeutics a public or private company?

Phanes Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Phanes Therapeutics founded?

Phanes Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Phanes Therapeutics based?

Phanes Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Phanes Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Phanes Therapeutics's main competitors?

Direct peers on record are Akeso, Astellas Pharma, Innovent Biologics, MacroGenics, Zymeworks, Compugen, Alphamab Oncology, Dragonfly Therapeutics and ABL Bio. BeiGene is listed as a broad incumbent.

Does Phanes Therapeutics have an API?

No public API is recorded for Phanes Therapeutics.

What industry is Phanes Therapeutics in?

Phanes Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacePhanes Therapeutics announces US patent granted to its proprietary bispecific antibody technology platform PACbody®Phanes Therapeutics announced the USPTO granted a patent for its PACbody bispecific antibody platform. The company's spevatamig advanced to Phase II trials with positive results at ASCO 2026. The patent strengthens IP protection for its core pipeline.Targeted OncologyFDA Fast Tracks PT886 in CLDN18.2+ Pancreatic CancerThe FDA has granted fast track designation to PT886, a bispecific antibody developed by Phanes Therapeutics, for the treatment of metastatic CLDN18.2-positive pancreatic adenocarcinoma. The drug targets CLDN18.2 and CD47 proteins and is currently being evaluated in the phase 1 TWINPEAK clinical trial for safety and efficacy. This regulatory milestone follows an orphan drug designation previously granted in 2022.CuretodayNew Trial Combines PT886 And Keytruda for Gastric CancerPhanes Therapeutics is conducting a phase 1 clinical trial to evaluate the combination of its investigational bispecific antibody PT886 and Merck's Keytruda for patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinomas. This effort follows a collaboration agreement between Phanes and Merck, aiming to leverage complementary mechanisms to improve patient outcomes where standard therapies have failed.Targeted OncologyTrial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ CancerPhanes Therapeutics has dosed the first patient in the TWINPEAK clinical trial, which evaluates the combination of its bispecific antibody PT886 and pembrolizumab for advanced gastric and gastroesophageal junction cancers. The phase 1/2 study aims to assess safety, tolerability, and preliminary efficacy across multiple dose levels.OncLiveFDA Grants Fast Track Designation to PT217 for Neuroendocrine Prostate CancerThe FDA has granted fast track designation to PT217, developed by Phanes Therapeutics, for the treatment of metastatic neuroendocrine prostate cancer. This agent is currently being evaluated in the SKYBRIDGE trial as a monotherapy or in combination with atezolizumab for various DLL3-expressing cancers. The designation marks the second such approval from the FDA for PT217, following its previous status for extensive-stage small cell lung cancer.OncLiveFDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract CarcinomaThe FDA has granted fast track designation to spevatamig (PT886) for the treatment of patients with advanced and metastatic biliary tract carcinoma. Phanes Therapeutics, the developer of the drug, is currently expanding clinical trial collaborations with Merck to study the agent in combination with pembrolizumab for first-line treatment of this cancer.Urology TimesFDA fast tracks PT217 for neuroendocrine prostate cancerThe FDA granted fast track and orphan drug designations to PT217, a bispecific antibody developed by Phanes Therapeutics, for the treatment of metastatic neuroendocrine prostate cancer. The designation supports the ongoing SKYBRIDGE phase 1/2 trial, which is evaluating the therapy's safety and efficacy in patients with DLL3-expressing neuroendocrine cancers across seven sites in the United States.CuretodayFirst Patient With Small Cell Lung Cancer Dosed With PeluntamigPhanes Therapeutics has dosed the first patient in its SKYBRIDGE clinical trial for peluntamig (PT217) combined with chemotherapy to treat small cell lung cancer and neuroendocrine carcinoma. The drug has previously received orphan drug and fast track designations from the FDA, and Phanes is collaborating with Roche on a separate evaluation involving Tecentriq.Pharmaceutical Business reviewFDA grants fast track status to Phanes’ spevatamig for advanced BTCPhanes Therapeutics received fast track designation from the US FDA for spevatamig to treat advanced and metastatic biliary tract carcinoma. This regulatory milestone follows previous designations for pancreatic cancer indications and coincides with an expanded clinical trial partnership with Merck & Co to evaluate the drug in combination with pembrolizumab.Pharmaceutical TechnologyFDA grants fast track status to Phanes' spevatamig for advanced BTCPhanes Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its drug spevatamig, intended to treat advanced biliary tract carcinoma (BTC). The drug is currently being evaluated in Phase II clinical studies in collaboration with Merck & Co (MSD), which was recently expanded to explore a combination therapy involving pembrolizumab. This designation follows other recent regulatory milestones for spevatamig related to metastatic pancreatic cancer.